Evaxion Biotech (EVAX) Stock Analysis & AI Equity Report
Evaxion Biotech (EVAX) overview
Evaxion Biotech (EVAX) stock analysis and AI equity research. For the latest completed financial year, 2025, Evaxion Biotech reported revenue of USD 7.5m and operating profit of USD -9.2m; the year-end share price was 4.77 USD and market capitalisation was USD 30.6m. Evaxion Biotech is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Evaxion Biotech's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Evaxion Biotech
Evaxion Biotech A/S is a Danish biotechnology company developing AI-based immunotherapies and vaccines through its AI-Immunology platform. Its work focuses on discovering and designing candidates for cancer, bacterial diseases and viral infections, with programs advancing through preclinical and clinical development. The company also relies on its AI prediction models as a core value driver.
Generate the Evaxion Biotech report
Evaxion Biotech is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Evaxion Biotech and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.